Neuroscience-focused biopharma selling multiple-sclerosis drugs and an Alzheimer's treatment (Leqembi, with Eisai).
Neuroscience-focused biopharma selling multiple-sclerosis drugs and an Alzheimer's treatment (Leqembi, with Eisai).
Earns from its own multiple-sclerosis drugs and from royalties on Ocrevus, a rival MS drug sold by Roche. Eisai books Leqembi sales and Biogen takes a share of the profit, so that drug adds income without showing up as Biogen product sales. Older MS medicines face generic competition.
Moat: narrow (IP / patents, installed base). Long-standing MS-specialist relationships and an early lead in disease-modifying Alzheimer's therapy.
Headquarters: Cambridge, Massachusetts, United States · Founded: 1978 · Employees: 7,500
Size Biogen (BIIB) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $37.2B, the 313th largest of 3,085 United States companies the cockpit tracks. Shares closed at $251.41 on 18 Nov 2026.
Performance Over six months the shares gained 33.9%, against +13.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 2.1% over the last twelve months (peer median +16.4%); the operating margin is 17.3% (peer median 18.2%).
Valuation It trades at 17.1× forward earnings against a peer median of 19.0× (9th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.1 points below its cost of capital (6.4% WACC).
Credit Biogen has 7 bonds outstanding ($5.45B), rated BBB+ by the agencies and trading like A- at a weighted spread of 91 bp.
Short interest Short interest is 3.7% of the free float (30 Oct 2026).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $9.90B | $9.53B | $9.27B | $9.42B | $9.43B |
| Revenue growth | — | +3% | -2% | 0% | — |
| Gross profit | $6.33B | $6.45B | $6.28B | $6.39B | $6.64B |
| EBITDA | $2.60B | $3.32B | $2.80B | $2.13B | $2.79B |
| Net income | $348M | $1.29B | $1.63B | $1.16B | $3.05B |
| Free cash flow | $2.07B | $2.05B | $2.72B | $1.27B | $1.14B |
| Capital expenditure | $603M | $235M | $360M | $311M | $243M |
| Total debt | $7.80B | $6.66B | $6.72B | $7.43B | $6.71B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 9.2× | -13.1% |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BIIB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.4% | +6.3% | 9th lowest of 21 |
| 6-month return | +33.9% | +13.3% | 4th highest of 21 |
| Distance from 52-week high | -3.7% | -9.1% | 4th highest of 21 |
| Revenue growth (TTM) | +2.1% | +16.4% | 5th lowest of 21 |
| Operating margin | 17.3% | 18.2% | 9th lowest of 21 |
| Forward P/E | 17.1× | 19.0× | 9th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 10.1% | 9.1% | 9th most demanding of 18 |
| Growth delivered (Del g) | -5.1% | +10.8% | lowest of 18 |
| Hurdle (Req g minus delivered) | +15.2 pp | +2.8 pp | 3rd most demanding of 18 |
| ROIC minus cost of capital | -1.1 pp | +4.8 pp | 4th lowest of 21 |
| EV / EBITDA | 16.8× | 21.7× | 8th cheapest of 17 |
| Net debt / EBITDA | 2.5× | 0.8× | 5th most indebted of 17 |
| Bond spread | 91 bp | 100 bp | 3rd tightest of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | Hong Kong | $44.9B | -24% | +11% | 27% | 28.1× | 9.1% | +2.0% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Wuxi Apptec 2359.HK | Hong Kong | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% | +20.4% |
Biogen has 7 bonds outstanding with $5.45B face value. The agencies rate it BBB+; its bonds trade like A-. Weighted yield 5.92%, a spread of 91 bp over government bonds.